|Articles|September 16, 2013
What is Misunderstood about RBM
A conversation with Marc Buyse, founder of CluePoints on risk based monitoring in clinical trials
Advertisement
A conversation with Marc Buyse, founder of CluePoints on risk based monitoring in clinical trials
This video is part of a series of conversations on
For more videos of Marc Buyse, see also:
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
FDA Approves Subcutaneous Lunsumio VELO Based on GO29781 Trial Results in Relapsed or Refractory Follicular Lymphoma
2
Applying AI to Automate Workflows Without Disrupting Sites
3
ACT Brief: Building a Digital Thread in Life Sciences, CRO Sourcing Decisions and Site Burden, and Lilly’s Oral GLP-1 Phase III Results
4
Life Sciences Can’t Afford Fragmented Data and Disconnected Teams
5